

TH!

DOCKET NO.: Y0087.70013US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

George et al.

Serial No.:

10/585,562

Confirmation No.:

4715

Filed: For:

June 30, 2006
COMBINATION THERAPY WITH MECAMYLAMINE FOR THE TREATMENT OF

MOOD DISORDERS

Examiner:

Not Yet Assigned

Art Unit:

1614

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 17th day of November, 2006.

Crena Pachec

MAIL STOP AMENDMENT

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- First Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:

Patricia Granahan, Reg(No.: 32,227

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: Y0087.70013US01 Date: November 17, 2006



DOCKET NO.: Y0087.70013US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

George et al.

10/585,562

Confirmation No.:

Filed:

June 30, 2006

For:

COMBINATION THERAPY WITH MECAMYLAMINE

FOR THE TREATMENT OF MOOD DISORDERS

Examiner:

Not Yet Assigned

Art Unit:

1614

4715

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 17th day of November, 2006.

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

1088548.1

Serial No.: 10/585,562 -2- Art Unit: 1614

Conf. No.: 4715

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

1088548.1

Serial No.: 10/585,562 - 3 - Art Unit: 1614

Conf. No.: 4715

Docket No.: Y0087.70013US01

Date: November 17, 2006

An early and favorable action is hereby requested.

Respectfully submitted,

By:

Patricia Granahan, Reg. (No. 32,227 Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

1088548.1

	SIPE WOR					
FORM PTO-1449/A and Branodified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICATION NO.: 10/585,562 ATTY. DOCKET NO.: YO		ATTY. DOCKET NO.: Y0087.70013US01	
			FILING DATE:	June 30, 2006	CONFIRMATION NO.: 4715	
			APPLICANT:	George et al.		
Sheet	1	of	1	GROUP ART UNIT:	1614	EXAMINER: Not Yet Assigned
Silect		V1		J		

U.S. PATENT DOCUMENTS

Examiner's	Cite No.	U.S. Patent Doc	ument	Name of Patentee or Applicant of Cited of	Date of Publication or Issue	
Initials #		Number	Kind Code		of Cited Document MM-DD-YYYY	
	A1	6,034,079		Sanberg et al.	03-07-2000	
		-	_			

FOREIGN PATENT DOCUMENTS

Examiner's	Cite	Foreign Patent Document			Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	Document Cited Document MM-DD-YYYY		(Y/N)
	B1	wo	99/07356	A1	University of South Florida Research Foundation Inc.	02-18-1999	
	B2	wo	99/17803	Al	Cary Medical Corporation	04-15-1999	
	B3	International Search Report. Application No.: PCT/US2005/000083. Mailing Date: June 8, 2005.					
	B4	Written Opinion. Application No.: PCT/US2005/000083. Mailing Date: June 8, 2005.					
	B5	International Preliminary Report on Patentability. Application No.: PCT/US2005/000083. Mailing					
		Date: July 20, 2006.					

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	CALDARONE et al., High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry. 2004 Nov 1;56(9):657-64.	
	C2	GATTO et al., Antidepressant-like effects of a subtype-selective neuronal nicotinic receptor ligand, TC-1707, in the forced swim test. Targacept Poster. 2001Nov; Annual Meeting of the Society of Neuroscience	
	C3	POPIK et al., Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram. Br J Pharmacol. 2003 Jul;139(6):1196-202.	

EXAMINER:	/Samira Jean-louis/	DATE CONSIDERED: 03/14/2009

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).